CURN EBS Week ended 31 Jul 2026

Weekly Investor Report

Curatis Holding AG · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 21.10 CHF
-10.2% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -1.2% below the Trend Line and sits at 60.0% of its 52-week range. The latest completed week returned -10.2%, after a -10.6% four-week move. The latest news-sentiment score is 55/100.

Setup score 55 out of 100
Latest Close 21.10 CHF 31 Jul 2026
1W Return -10.2% latest completed week
4W Return -10.6% short-term follow-through
12W Return -8.7% quarterly tape
Trend Breadth 88.5% 46 of 52 weeks active
Volume Ratio 1.6x vs 13-week average
What is working
  • The trend backdrop is active with a 29-week active streak.
  • Price is above Fair Value, showing premium demand versus the model.
  • Volume is elevated versus the 13-week average, confirming attention.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -10.2% Latest completed week; four-week move -10.6%. Indicator stack 94/32 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 55/100 7 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -1.2% below the Trend Line and sits at 60.0% of its 52-week range. The latest completed week returned -10.2%, after a -10.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8412-week average 0.93

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.84Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.6% over four weeks, -8.7% over 12 weeks, and 73.0% over one year. The current trend has remained active for 29 consecutive weeks.

Performance by holding period

1W-10.2%
4W-10.6%
12W-8.7%
26W26.3%
52W73.0%
Active trend streak29 weeks
Active weeks in one year46
Trend breadth88.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.89Latest activity-pressure read.
Pressure change-27.4%Four-week change in activity pressure.
Leadership9.94Latest relative-leadership reading.
RS change-63.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

A published fundamentals and factor snapshot is not available for this company.

Open full factor analysis

No published fundamental snapshot is available for this company.

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 7 relevant articles.

2 positive · 5 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-24.4%Distance below the 52-week high.
13-week volatility4.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+36.6%Week of 13 Mar.
Worst week-10.2%Week of 31 Jul.
Latest week-10.2%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains8
Flat weeks0
Modest losses5
Sharp losses6
Recent vol4.9%13-week weekly-return volatility.
Base vol7.8%52-week weekly-return volatility.
Up/down split25/25Count of positive and negative weeks in the 52-week window.
Average skew6.5% / -3.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape62/100

Trend, activity pressure, participation, and risk combine to a 62/100 tape read.

 Indicator analysis75/100

Latest 12-week confirmation: trend 12/12, activity pressure 4/12, relative leadership 12/12.

Activity pressure 0.84; No reversal markers Factors50/100

No published factor snapshot is available yet.

 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 7 relevant articles.

Biotech companies Veraxa and Curatis strengthen financial positions Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202621.10 CHF-10.2%21.36 CHF13.52 CHF-0.899.9416.4KOn
24 Jul 202623.50 CHF2.6%21.06 CHF13.60 CHF-0.7823.392.7KOn
17 Jul 202622.90 CHF-6.5%20.66 CHF13.71 CHF-0.7421.367.0KOn
10 Jul 202624.50 CHF3.8%20.27 CHF13.78 CHF-0.6932.167.2KOn
3 Jul 202623.60 CHF0.9%19.86 CHF13.88 CHF-0.7027.154.0KOn
26 Jun 202623.40 CHF-1.3%19.49 CHF13.99 CHF-0.6829.80585On
19 Jun 202623.70 CHF2.2%19.12 CHF14.12 CHF-0.3436.684.3KOn
12 Jun 202623.20 CHF1.3%18.74 CHF14.26 CHF-0.0835.946.3KOn
5 Jun 202622.90 CHF-8.0%18.38 CHF14.41 CHF0.1738.92597On
29 May 202624.90 CHF4.2%18.03 CHF14.58 CHF0.5451.1526.6KOn
22 May 202623.90 CHF5.8%17.62 CHF14.76 CHF0.6347.5914.5KOn
15 May 202622.60 CHF-2.2%17.26 CHF14.94 CHF0.9044.1023.0KOn
8 May 202623.10 CHF-5.3%16.96 CHF15.15 CHF1.0750.6923.5KOn
1 May 202624.40 CHF-2.4%16.65 CHF15.37 CHF1.1061.094.6KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.